Global patient organisation funding

GAAPP – Global Allergy and Asthma Patient Platform

GAAPP is a global association of organisations advocating the rights and interests of people living with allergies and airways diseases. GAAPP was established in 2011 in Istanbul, Turkey, during the EAACI meeting. Currently, GAAPP consists of 42 member organisations on all continents. The mission of GAAPP is to support patients with allergies and airways diseases throughout the world by protecting their rights and insisting on the duties of governments, healthcare professional organisations and the general public.

We have supported this group since 2013.

During 2020:
GSK provided a total of £76,876:

- £17,992 in support of the Global Respiratory Summit that brought together respiratory advocacy organisations to share best practices, to build organisational capacity and leverage the collective voice to advance progress in respiratory disease in the noncommunicable disease policy arena.
- £1,799 in support of the LATAM Patient Summit, organised by GAAPP and the Lovexair Foundation, that provided a series of free sessions and workshops to the community. These meetings provided tools and new perspectives to improve training and management in respiratory health in this new Covid context.
- £55,000 in support of Define Your Asthma 2020 campaign that provided a suite of social media assets for use by member organisations at a local level.
- £2,085 consultancy fee for attendance at GSK’s Patient Advocacy & Advisory Board (PAAB)

Our support represented 11.73 % of their overall income.

During 2019:

- We provided £3,325 GAAPP consultancy fee for attendance at GSK’s Patient Advocacy Advisory Board (PAAB). We also provided travel and accommodation for this meeting.
- We provided £82,794 in-kind support for the Define your Asthma campaign that provided a suite of educational and awareness communications materials for use by member organisations at a local level.
- We provided £14,275 in-kind support for the Patient Understanding Leading to an appropriate Severe Asthma Referral initiative (PULSAR), aiming to develop and disseminate a global, patient centred definition of severe asthma in order to help improve patient understanding and change patient behaviour.
- We provided a £30,000 grant to support a two-day global summit on respiratory health that was co-hosted by COPD Global and GAAPP, bringing together respiratory advocacy organisations to share best practices, build organisational capacity and leverage the collective voice to advance progress in respiratory disease in the noncommunicable disease policy arena.
Our support represented 18.4% of their overall income.

**During 2018**

- We provided £929 GAAPP consultancy fee for attendance at GSK’s Patient Advocacy Advisory Board (PAAB).
- We provided £61,929 in-kind support for the Define your Asthma campaign that provided a suite of social media assets for use by member organisations at a local level.
- We provided a Medical grant of £34,000 for GAAPP to develop educational resources.
- We provided £65,629 in-kind support for the Patient Understanding Leading to an appropriate Severe Asthma Referral initiative (PULSAR), aiming to develop and disseminate a global, patient centered definition of severe asthma in order to help improve patient understanding and change patient behaviour.

Our support represented 35% of their overall income.

**During 2017**

- We provided a restricted grant of €28,500 for raising awareness of Severe Asthma characteristics, diagnosis and treatment options.

Our support represents 21.86% of their overall income.